Amvuttra (vutrisiran) is FDA-approved to treat nerve damage caused by hereditary transthyretin-mediated (hATTR) amyloidosis. Clinical trials, like Helios-A, have shown it effectively reduces TTR protein levels and improves symptoms of peripheral neuropathy. However, its long-term effectiveness is still being studied. Always Show Full Answer

Amvuttra (vutrisiran) is FDA-approved to treat nerve damage caused by hereditary transthyretin-mediated (hATTR) amyloidosis. Clinical trials, like Helios-A, have shown it effectively reduces TTR protein levels and improves symptoms of peripheral neuropathy. However, its long-term effectiveness is still being studied. Always monitor your progress with your doctor to ensure the treatment is working for you. For more details, visit: [Amvuttra](https://www.myamyloidosisteam.com/treatments/am...).

 This AI-generated response comes from MyAmyloidosisTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

hATTR Amyloidosis Treatments: Comparing Your Options | MyAmyloidosisTeam

Amvuttra (Vutrisiran) for Amyloidosis | MyAmyloidosisTeam